Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Michael Dennis, FRCPath, Robert K Hills, DPhil, Ian Thomas, Sunil Gupta, MBBS, MRCP, FRCPath, Nicki Panoskaltsis, MD, Mhairi Copland, PhD BSc, MB, ChB, MRCP, FRCPath, Alan K. Burnett, MD FRCP, Nigel H Russell, MD

Blood (2016) 128 (22): 2827.

https://doi.org/10.1182/blood.V128.22.2827.2827

Published: 2016

Journal Articles

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Nigel H Russell, MD, Alan K. Burnett, MD FRCP, Robert K Hills, DPhil, Sophie Betteridge, PhD, Michael Dennis, FRCPath, Richard Dillon, MA, MRCP, FRCPath, David Grimwade, PhD FRCPath

Blood (2016) 128 (22): 897.

https://doi.org/10.1182/blood.V128.22.897.897

Published: 2016

Journal Articles

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

Robert K Hills, DPhil, Guy Gammon, MBBS,MRCP, Denise Trone, Alan K. Burnett, MD FRCP

Blood (2015) 126 (23): 2557.

https://doi.org/10.1182/blood.V126.23.2557.2557

Published: 2015

Journal Articles

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

Nigel H. Russell, MD, Robert K Hills, DPhil, Sylvie Freeman, PhDFRCPath, Steven Knapper, Lars Kjeldsen, MD PhD, Ian Thomas, Jamie Cavenagh, Paul Cahalin, Mary Frances McMullin, MD FRCPath, FRCP, Alan K. Burnett, MD FRCP

Blood (2015) 126 (23): 221.

https://doi.org/10.1182/blood.V126.23.221.221

Published: 2015

Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD

Blood (2015) 126 (23): 559.

https://doi.org/10.1182/blood.V126.23.559.559

Published: 2015

Journal Articles

Prognostic Significance and Risk Stratification in Acute Myeloid Leukaemia Patients in the Absence of Successful Cytogenetic Analysis

Lucy Chilton, PhD, Christine Harrison, PhDFRCPath FMedSci, Anthony V. Moorman, PhD, Iona Ashworth, Alan K. Burnett, MD FRCP, David Grimwade, PhD FRCPath, Robert K Hills, MA MSc DPhil

Blood (2015) 126 (23): 1379.

https://doi.org/10.1182/blood.V126.23.1379.1379

Published: 2015

Journal Articles

Regulation of ABCB1 (p-glycoprotein) by the FOXO1 Transcription Factor in Acute Myeloid Leukemia.

Claire Seedhouse, PhD, Sophie Ahluwalia, BSc, Ken I Mills, Ph.D., FRCPath, Martin Grundy, BSc, Shili Shang, MD, MSc, Alan K. Burnett, MD, FRCP, Nigel H. Russell, MD, Monica Pallis, PhD

Blood (2009) 114 (22): 589.

https://doi.org/10.1182/blood.V114.22.589.589

Published: 2009

Journal Articles

The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy

Carol Guy, Amanda Gilkes, Rosemary Gale, PhD, David C. Linch, FRCP, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP

Blood (2008) 112 (11): 2978.

https://doi.org/10.1182/blood.V112.11.2978.2978

Published: 2008

Journal Articles

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Robert Hills, MA, MSc, DPhil, Susan O’Brien, M.D., Verena Karsten, PhD, Alan K. Burnett, MD, FRCP, Francis Giles, MD

Blood (2008) 112 (11): 2960.

https://doi.org/10.1182/blood.V112.11.2960.2960

Published: 2008

Journal Articles

Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison

Alan K. Burnett, MD, FRCP, Robert Hills, MA, MSc, DPhil, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Andres E. Virchis, FRCP, FRCPath, Nigel H. Russell, MD

Blood (2008) 112 (11): 2962.

https://doi.org/10.1182/blood.V112.11.2962.2962

Published: 2008

Journal Articles

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Jacob M. Rowe, MD, Georgina Buck, Anthony V Moorman, MD, Martin S Tallman, MD, Susan M Richards, Ph.D, Adele K Fielding, MD, Ph.D, Alan K. Burnett, MD, FRCP, Ian M Franklin, MD, Peter H. Wiernik, MD, Hillard M Lazarus, MD, Elisabeth Paietta, PhD, Mark R. Litzow, MD, David I Marks, MD, Selina Luger, MD, Gordon W. Dewald, PhD, PhD, FACMG, Anthony H. Goldstone, FRCP, FRCPath

Blood (2008) 112 (11): 3314.

https://doi.org/10.1182/blood.V112.11.3314.3314

Published: 2008

Journal Articles

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

Marc R Mansour, MBChB, MRCP, Rosemary Gale, PhD, Asim Khwaja, Martin Pule, Robert Hills, MA, MSc, DPhil, Alan K. Burnett, MD, FRCP, David Linch

Blood (2008) 112 (11): 3364.

https://doi.org/10.1182/blood.V112.11.3364.3364

Published: 2008

Journal Articles

Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial

John Liu-Yin, FRCP, FRCPath, Michelle Sale, MSc, Sarah Daly, PhD, Robert Hills, MA, MSc, DPhil, Keith Wheatley, DPhil, Alan K. Burnett, MD, FRCP

Blood (2008) 112 (11): 697.

https://doi.org/10.1182/blood.V112.11.697.697

Published: 2008

Journal Articles

Determining the Appropriate PCR Trigger for Pre-Emptive Anti-CMV Therapy in Allogeneic Stem Cell Transplant Recipients.

Unmesh Mohite, MD, MRCPath, Diana Westmoreland, FRCPath, Una O’Callaghan, MB, MRCP, MRCPath, Alan K. Burnett, MD, FRCP, FRCPath, Keith M.O. Wilson, MRCP, MRCPath

Blood (2006) 108 (11): 5281.

https://doi.org/10.1182/blood.V108.11.5281.5281

Published: 2006

NARROW

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Prognostic Significance and Risk Stratification in Acute Myeloid Leukaemia Patients in the Absence of Successful Cytogenetic Analysis

Regulation of ABCB1 (p-glycoprotein) by the FOXO1 Transcription Factor in Acute Myeloid Leukemia.

The Impact of MN1 Over-Expression on the Outcome of Younger Patients with AML Treated with Intensive Chemotherapy with or without ATRA Therapy

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison

Standard Consolidation/Maintenance Chemotherapy Is Consistently Superior to a Single Autologous Transplant for Adult Patients with Acute Lymphoblastic Leukemia: Results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

CSL-TREX: A Novel Alternatively Spliced Isoform of CSL (RBPJ-K) Predominates Over the Full-Length Isoform in Many Patients with Acute Myeloid Leukaemia, Can Activate Notch Signalling and Is Associated with Improved Outcome.

Predictive Value of Minimal Residual Disease (MRD) Monitoring by RQ-PCR in WT1 Positive Patients Entered in the UK MRC AML-15 Trial

Determining the Appropriate PCR Trigger for Pre-Emptive Anti-CMV Therapy in Allogeneic Stem Cell Transplant Recipients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only